Sleep Quality & Psoriatic Arthritis
For people living with psoriatic arthritis (PsA), the comfort of a good night's sleep may feel out of reach for many.
Read more →What's hot!
View all perspectives
What's Hot
Ultrasound in PsA
Dr. Arthur Kavanaugh discusses abstract 2206 presented at ACR22 in Philadelphia. Abstract 2206: Understanding Inter-rater Variability in Scoring of Entheseal Lesions: Results from the Diagnostic Ultrasound Enthesitis Tool (DUET) Study
Watch video →
Tapering TNFi in nonradiographic AxSpA
Dr. Peter Nash at ACR22 Convergence in Philadelphia, PA.
Watch video →
Sunday (Day 2): ACR 22 Daily Recap
ACR 2022 Daily Recap for Sunday, November 13th. Panelists: Drs. Robert Chao, Antoni Chan, Bella Mehta, Janet Pope, Yuz Yusof, Cassy Sims, Akhil Sood, Sheila Reyes and Jack Cush.
Watch video →
Spondyloarthritis: Novel Therapies, Diagnostic Dilemmas and Depression
Dr. Lianne Gensler discusses the following abstracts presented at ACR22 Convergence. Abstracts 1597, 1598, 1599 (treatment) and 1613, 1609 and 1614 (diagnosis and outcomes)
Watch video →
Deucravacitinib in PsA
Dr. Arthur Kavanaugh discusses abstract 1598 at ACR22 Convergence in Philadelphia. Abstract 1598: Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial
Watch video →
PET CT Imaging to Define Risk of Progression from PSO to PsA
Dr. Peter Nash discusses Abstract 1018 at ACR22 Convergence.
Watch video →
ACR22 Daily Recap: Saturday Recap
Panelists: Drs. Jack Cush, Michael Putman, Eric Dein, Patricia Harkins and Rachel Tate.
Watch video →
The Great Debate: To Treat or Not to Treat Pre RA
Dr. Janet Pope and Dr. Jonathan Kay discuss the Great Debate, which Dr. Pope participated in, at ACR22 Convergence in Philadelphia, PA.
Watch video →
COVID Highlights
Dr. Leonard Calabrese and Dr. Cassandra Calabrese share highlights on COVID data being presented at ACR22 Convergence. Abstract 0793: Autonomic Nervous System Dysfunction Common Among Patients with Long COVID: An Exploratory Evaluation Abstract L08: Breakthrough Acute COVID-19 Infection During the US Omicron Surge Following Administration of Tixagevimab/Cilgavimab in Immunocompromised Patients with Rheumatologic Disorders
Watch video →
To Switch or Not: Biosimilars in Inflammatory Arthritis
Dr. Jonathan Kay reports on abstract 1112 at ACR22 Convergence.
Watch video →
Switch vs Cycle in PsA
Dr. Arthur Kavanaugh discusses abstract 1600 at ACR22 Convergence. Abstract 1600: The Impact of Second-Line Therapeutic on Disease Control After Discontinuation of First Line TNF Inhibitor in Patients with PsA: Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Watch video →
New Treatments for SLE?
Dr. Michelle Petri discusses abstract 1117 presented at ACR22 Convergence meeting in Philadelphia, PA. Abstract 1117: Efficacy and Safety of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in Patients with Active Systemic Lupus Erythematosus: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
Watch video →
Best of PsA on Day 1
Dr. Rachel Tate discusses the best PSA data presented Saturday, November 12, 2002 at ACR22 Convergence. Abstract 0387: Sleep Quality in Patients with Psoriatic Arthritis and Its Relationship with Activity and Comorbidity Abstract 0377: Differences in Early-onset vs. Late-onset Psoriatic Arthritis: Data from the RESPONDIA and REGISPONSER Studies
Watch video →
Urinary Biomarkers in Lupus
Dr. Jack Cush interviews Dr. Andrea Fava about Abstract 536 at the ACR22 Convergence meeting in Philadelphia, PA. Abstract 0536: Change in Urinary Biomarkers at Three Months Predicts 1-year Treatment Response of Lupus Nephritis Better Than Proteinuria
Watch video →
A Novel Treatment Response Measurement Tool for Lupus
Dr. Kathryn Dao discusses abstract 2054 with Dr. Eric Morand at the ACR22 Convergence meeting. Abstract 2054: Towards a Novel Clinician-Reported Outcome Measure for SLE – Outcomes of an International Consensus Process.
Watch video →
sheila RHEUMarampa
3 years 10 months ago
Dr. Coldiron (thru case examples) shares how the MSF works in providing medical care to pts in areas of conflict or crisis & how #climate change has also impacted health, including #Mentalhealth
#ACR22 @RheumNow @rheumarhyme https://t.co/gFuX4sL0WA
TheDaoIndex KDAO2011
3 years 10 months ago
50 yo hispanic male +MDA5 Ab w/ synovitis, skin lesions, neg ANA, normal CK, aldolase, +MDA5 Ab, Skin biopsy show changes c/w dermatomyositis. Failed MTX/MMF, no insurance. What is MDA5's role? Does race play a factor in Rx response? What is your next step? @rheumnow #ACR22 https://t.co/tGy2BH6y45
TheDaoIndex KDAO2011
3 years 10 months ago
Dr. R Puligari:
55 yo female w/arthritis, rash, DOE, fever, weight loss, CT abnormal +MDA5 dermatomyositis: Rx RTX, IV steroids, CYP, TAC and Ofev. Disease progressed; IVIG,steroids, PLEX added w/benefits. 6 months later had CMV retinitis. What to do next? #ACR22 @rheumnow https://t.co/A1m8HMtCob
Janet Pope Janetbirdope
3 years 10 months ago
#ClinicalPearl #Methotrexate is recommended for Rx in all EXCEPT…#ACR22 @RheumNow
TheDaoIndex KDAO2011
3 years 10 months ago
Dr. M Tikly share #rheum challenges & solutions in South Africa:
👉⬆️training to gen. practitioners & nurses, 👉estab outreach clinics
👉lobby local government/political groups
👉use of off-label drugs
👉engage pharma: free meds/clinical trials #ACR22 #GlobalHealth @rheumnow https://t.co/BX2qXk1usN
sheila RHEUMarampa
3 years 10 months ago
Dr. Tikly discusses the solutions to drug access challenges in South Africa in both state and private sectors 👇
🔸Off label use, buyouts, price⬇️, advocacy...
Highly relatable because these are similar challenges we face in the PH @rheumarhyme @doktora_ging
#ACR22 @rheumnow https://t.co/ajshylgtIE
David Liew drdavidliew
3 years 10 months ago
Finally we're starting to get therapies for polymyalgia rheumatica!
The best of PMR therapeutics coming up at #ACR22 (and catch it all @RheumNow): https://t.co/lUPICA3Mim
Dr. John Cush RheumNow
3 years 10 months ago
#ACR22 Presents New Data on JIA Clinical Remission with Combo DMARDSs
New research being presented at #ACR22, demonstrated that polyarticular juvenile idiopathic arthritis patients were more likely to achieve clinical remission with combo DMARDSs.
https://t.co/qmfnEvDedA https://t.co/VhkYlZJG3s
Dr. John Cush RheumNow
3 years 10 months ago
Update: axSpA Recommendations
https://t.co/KaBb11WLQD https://t.co/8kIaa0WuvM
Dr. John Cush RheumNow
3 years 10 months ago
Study of 78 824 adults shows Prevalence of Cannabis use was significantly higher during the pandemic vs before the pandemic in states where it is legalized (but not increase in nonlegal states) esp in adults 18 to 29 and 30 to 54 years https://t.co/ZZzCl7dstj https://t.co/qbQLPhI6I8
Rheumatoid arthritis treatment has come leaps and bounds in recent decades. Gone are the days of gold injections, chemical synovectomies, and physician-mandated bedrest (heaven forbid). Though the marketplace for RA treatments is becoming ever more crowded, there are still unmet needs.
The updated 2022 EULAR recommendations for the management of rheumatoid arthritis (RA) were initially presented by Dr. Josef Smolen at EULAR 2022, and are now in press delineating the most recent developments and perspectives in RA treatment.
Dr. John Cush RheumNow
3 years 10 months ago
FDA issues an Emergency Use Authorization (EUA) for anakinra (Kineret) to treat Hospitalized COVID-19+ Patients with pneumonia requiring supplemental
O2 & ! risk for respiratory failure or increased suPAR levels https://t.co/t5gFULIhCH
Dr. John Cush RheumNow
3 years 10 months ago
Dr. Yuz Yusof will be covering #ACR22 as a RheumNow reporter again. He'll be sharing real-time coverage on SLE, auto-inflammatory and COVID.
Follow @Yuz6Yusof! https://t.co/3rYlIrM54m
Dr. John Cush RheumNow
3 years 10 months ago
Chronic Pain increased from 2010-2919. A cross-sectional study of 46 420 respondents, shows nonpharmacologic Rx increased [aOR 2.72] & was greater than opioids for chronic, but not surgical pain. Govt policy & practice guidelines have helped. https://t.co/31oS0xWRMW https://t.co/IvkDRJQvT8
